Tritiated thymidine labeling index and response in human breast cancer

Aaron Sulkes, Robert B. Livingston, William K. Murphy

Research output: Contribution to journalArticlepeer-review

69 Scopus citations


Tumor cell uptake of tritiated thymidine, expressed as the labeling index (LI), was determined prior to treatment of 25 patients with disseminated breast carcinoma. All patients subsequently received combination chemotherapy with adriamycin, cyclophosphamide, and an antimetabolite (usually 5-fluorouracil), with or without vincristine. The LI was significantly higher in responders to chemotherapy than in nonresponders (mean, 15 vs. 7.1; P<0.01). Other pretreatment variables examined did not show a significant association with likelihood of response. Measurements of the tumor cell LI in patients with accessible tumor may be of benefit in selection of treatment; 0 of 9 patients with an LI less than 9 had a response in our series in contrast to 11 of 16 patients with an LI greater than 9 who had a response (P= 0.001).

Original languageEnglish (US)
Pages (from-to)513-515
Number of pages3
JournalJournal of the National Cancer Institute
Issue number3
StatePublished - Mar 1979
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Tritiated thymidine labeling index and response in human breast cancer'. Together they form a unique fingerprint.

Cite this